All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.

More information on our cookie policy.

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Artificial intelligence
    • Coronavirus
    • IVDs on the rise
    • Top Biopharma Trends of 2021
    • Top Med-tech Trends of 2021
    • Premium reports
      • BioWorld Financings Reports
      • Disease Incidence & Prevalence Summaries

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Sunday, May 22, 2022

Deals and M&A

  • Deals and M&A
    • Acquisition
    • Asset purchase
    • Collaboration
    • Co-promotion
    • Development
    • Distribution
    • Equity option
    • Government supply contract
    • Grant
    • Joint venture
    • License
    • Merger
    • Non-profit
    • Research
    • Research only
    • Reverse merger
    • Royalty buyout
    • Service agreement
    • Settlement
    • Spinout
    • Supply only
Home » Topics » Deals and M&A
  • Sidekick atopic dermatitis
    May 20, 2022
    By Annette Boyle

    Sidekick pumps its game up a step with Pfizer partnership

    Sidekick Health AB expanded its partnership with Pfizer Inc., adding an atopic dermatitis offering to its integrated digital therapeutics solution. The app will roll out first in the U.K., followed by Belgium, Norway, Netherlands, Sweden, France, Ireland and Japan this year.
  • Arrows opposite directions
    May 20, 2022
    By Randy Osborne

    Parting shot: Bayer decides against Atara but exit wound minor

    Atara Biotherapeutics Inc. is keeping the faith and figuring out next steps with its next-generation, mesothelin-directed CAR T-cell therapies after Bayer AG ended their exclusive worldwide licensing agreement, signed in late 2020. The setup included funding and development of ATA-3271, an armored allogeneic T-cell immunotherapy, and an autologous version, ATA-2271, for high mesothelin-expressing tumors such as malignant pleural mesothelioma and non-small-cell lung cancer.
  • May 19, 2022
    By Cormac Sheridan

    Almirall taps into Evotec discovery platform in dermatology alliance

    Evotec AG and Almirall SA have entered a multitarget drug discovery alliance focused on severe skin disease, from which Evotec could earn up to €230 million (US$243.5 million) in per-program milestones. It is also receiving an undisclosed up-front payment, research funding and, should any products reach the market, it would also bank sales royalties in the high-single-digit percentage range.
Read More

Authors

  • Jihyun Kim
  • Lee Landenberger
  • Nuala Moran
  • Tamra Sami
  • Randy Osborne
  • Michael Fitzhugh
More Authors

Pages

  • Med-tech M&As in 2022
  • Med-tech collaborations in 2022
  • Biopharma M&As in 2022
  • Biopharma collaborations in 2022
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Archives
    • Today's news
    • Search BioWorld Science
    • About
  • More
    • About
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
Follow Us

Copyright ©2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing